AMD: out of sight out of mind.
Pountney
David
D
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D003362:Cost-Benefit Analysis; D017277:Drug Approval / Q000458:organization & administration*; D016527:Drug Costs; D004363:Drug Utilization; D005851:Geriatric Nursing / Q000458:organization & administration; D006293:Health Promotion; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000451:nursing; D024802:Nurse's Role; D009885:Ophthalmology / Q000458:organization & administration; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000458:organization & administration; D000069579:Ranibizumab; D012307:Risk Factors; D013222:State Medicine / Q000458:organization & administration; D016896:Treatment Outcome; D006113:United Kingdom
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab